Cornerstone Robotics Ltd. raised an oversubscribed $200 million series D round to accelerate commercialization of its ...

In a deal worth up to $840 million, Third Arc Bio Inc. is licensing Adagene Inc.’s Safebody technology platform to generate ...

Merck & Co. Inc. is buying Cidara Therapeutics Inc. for $9.2 billion to acquire a late-stage flu candidate and also to ...

A251, a novel HER2 antibody-drug conjugate (ADC) designed to deliver a potent PI3K/PIKK inhibitor directly to tumor cells.

Withings SA received U.S. FDA clearance for Beamo, its health check-up tool designed to monitor heart and lung function. Described as the ‘thermometer of the future’, Beamo combines the sensors of an ...

ABL Bio Inc. inked a license and research agreement with Eli Lilly and Co. worth up to $2.6 billion to develop multiple ...

Siemens AG will deconsolidate its remaining 67% stake in Siemens Healthineers AG to a significant minority as it looks to ...

The U.K. government has published a road map for phasing out animal testing in life sciences research and announced £75 ...

A team of five members of the U.S. FDA staff published a review of the use of AI in health care and concluded that while ...

Biopharma companies focused on infectious disease extended their stock recoveries through the third quarter (Q3), with the BioWorld Infectious Disease Index closing October up 28.98%. The gain marks a ...

At first glance, the results of the CLOSURE-AF study would seem to spell doom for left atrial appendage closure devices for ...

Biopharma happenings, including deals and partnerships, and other news in brief: Century, Charm, Daiichi, Day One, Decoy, Flightpath, General Proximity, Kaken, Mersana, Metsera, Novo Nordisk, Numab, ...